Yesterday Actinogen announced the initial results from its Phase II clinical trial of Xanamem in patients with mild dementia due to Alzheimer’s disease (AD). The safety of the drug was confirmed and the data showed Xanamem was effectively inhibiting cortisol production, as demonstrated by the expected increase in adrenocorticotropic hormone. However, the 10mg dose of Xanamem was not effective in demonstrating statistical significance on any of the endpoints. We note that both primary an
08 May 2019
Actinogen Medical - Phase II XanADu trial results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Actinogen Medical - Phase II XanADu trial results
Actinogen Medical Limited (ACW:ASX) | 0 0 -9.4% | Mkt Cap: 35.9m
- Published:
08 May 2019 -
Author:
Dr Jonas Peciulis -
Pages:
2
Yesterday Actinogen announced the initial results from its Phase II clinical trial of Xanamem in patients with mild dementia due to Alzheimer’s disease (AD). The safety of the drug was confirmed and the data showed Xanamem was effectively inhibiting cortisol production, as demonstrated by the expected increase in adrenocorticotropic hormone. However, the 10mg dose of Xanamem was not effective in demonstrating statistical significance on any of the endpoints. We note that both primary an